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To the Editor:  
The letter by Batinic-Haberle et al. in response to our review is symptomatic for our exciting 
field of redox biology and medicine, although we disagree with its aggressive and in part 
nonscientific style. Their focus appears to be on redox biology, whereas the focus of our 
review was on redox medicine, in particular those drugs and applications already in clinical 
practice or in advanced clinical development rather than of ‘‘potential’’ or ‘‘future’’ clinical 
relevance. It was beyond the scope of our review to address the wide field of redox biology or 
experimental antioxidant reagents. Batinic-Haberle et al. provide a good overview of redox-
active compounds that, based on preclinical data, might hold some promise for clinical 
developments. To our knowledge, however, just a few of these compounds had entered a 
phase I trial at the time of writing our review, and none of them had progressed to phase II. 
One exception is mitoQ for which several phase II trials have been carried out in Parkinson’s 
disease, aging, nonalcoholic fatty liver disease, and hepatitis C, although none of these trials 
has been conclusive. In addition, the phase III study 2CARE for Huntington’s disease has been 
halted prematurely as a result of lack of efficacy of coenzyme Q10 (http:// 
huntingtonstudygroup.org/tag/2care/). Batinic-Haberle et al. specifically criticize that 
superoxide dismutase (SOD) mimetics were not mentioned, when in fact our review did 
mention some of these compounds, although maybe not the ones favored by these authors. 
AEOL 10150 may be an interesting antioxidant, but it has been at an early clinical stage of 
development for many years. Moreover, a phase I trial with amyotrophic lateral sclerosis (also 
known as Lou Gehrig’s disease and Charcot disease) patients in 2005 did apparently not 
progress, and in January 2015, the FDA put a clinical hold on AEOL 10150 (www.marketwired 
.com/press-release/aeolus-announces-response-fda-clinicalhold-plan-clinical-development-
aeol-10150-otcqb-aols- 1981367.htm). MnSOD mimetics were also discussed in cancer 
prevention and chronic obstructive pulmonary disease, but clinical trials are lacking (5). Other 
related compounds for which the authors of the letter appear to have a special interest, such 
as BMX-010 and BMX-001, are, to our knowledge, still in phase I, and we note that some of the 
authors of the letter hold patents for some of these compounds and are supported by the 
company developing them (i.e., Biomimetix Pharmaceutical, Inc). Conversely, the SOD mimetic 
mentioned in our review, GC4419, as being, at that time, in phase IIa was meanwhile shown to 
protect patients from side effects of radiotherapy 
(www.evaluategroup.com/Universal/View.aspx?type=Story &id=616252). Based on these 
clinical trial results, the US FDA has granted ‘‘Fast-Track’’ status to this agent in December 
2015 and the compound is now in a phase IIb/IIIa human clinical trial in the United States at 
several major cancer treatment centers and shall be completed in approximately 1–2 years. To 
the best of our knowledge, this development stage is the most advanced in the field and it is 
thus appropriate to have focused on this compound. We note that the letter of Batinic-Haberle 
et al. also contains a textbook-style lecture on SOD catalysis being a one-electron process. We 
agree, of course, that true SOD catalysis is a one-electron process. However, the same is not 
the case for the Mn(porphyrin) complexes described by Batinic-Haberle et al., as these also 
carry out multiple electron processes. For example, the same group reported Mn(porphyrin) 
complexes to also be good ‘‘catalase’’ mimics and others described them as efficient 
peroxynitrite decomposition catalysts.  
Thus, they are not only selective for superoxide removal but also react with the product of the 
dismutation, hydrogen peroxide, and the secondary oxidant, peroxynitrite. This may or may 
not be clinically useful or relevant, but mechanism is something that must be noted when 
discussing pharmacology of a pharmaceutical agent. Furthermore, it is irritating that the 
authors attempt to discount other compounds that are currently in human clinical trials [e.g., 
Mn(II)pentaazamacrocyclic ligand complexes] by claiming that they are acid unstable. This is 
misleading given that some of the authors of this letter have reported previously on the high 
kinetic and thermodynamic stability of members of this class of compounds (e.g., M40403). In 
fact, compounds of this class, including GC4419, are largely unmetabolized (>90% unchanged) 
and excreted almost entirely intact. In summary, given the focus of our review on the 
advanced clinical stage of antioxidant drugs, we consider it free of obvious bias, including 
conflict of interest. By comparison, it would have been appropriate for the authors of the 
letter, in the version provided to us, to state any potential conflict of interest that may have 
contributed to their choice of compound(s). 
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